These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38380739)

  • 1. EHMT2/G9a and EZH2: Epimarkers in testicular germ cell tumors.
    Estevão-Pereira H; Guimarães-Teixeira C; Flores BCT; Moreira-Silva F; Tavares NT; Guimarães R; Braga I; Maurício J; Henrique R; Jerónimo C; Lobo J
    Andrology; 2024 Feb; ():. PubMed ID: 38380739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome.
    Lobo J; Alzamora MA; Guimarães R; Cantante M; Lopes P; Braga I; Maurício J; Jerónimo C; Henrique R
    Andrology; 2020 Sep; 8(5):1233-1242. PubMed ID: 32384200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis.
    Ishiguro K; Kitajima H; Niinuma T; Maruyama R; Nishiyama N; Ohtani H; Sudo G; Toyota M; Sasaki H; Yamamoto E; Kai M; Nakase H; Suzuki H
    Cell Death Discov; 2021 Jan; 7(1):7. PubMed ID: 33436557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma.
    Jones TD; Ulbright TM; Eble JN; Baldridge LA; Cheng L
    Am J Surg Pathol; 2004 Jul; 28(7):935-40. PubMed ID: 15223965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and prognostic significance of chromatin modulators EHMT2/G9a and KDM2b in acute myeloid leukemia.
    Gouda MBY; Zidane MA; Abdelhady AS; Hassan NM
    J Cell Biochem; 2022 Aug; 123(8):1340-1355. PubMed ID: 35696556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D2-40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: a comparative immunohistochemical study with KIT (CD117) and CD30.
    Lau SK; Weiss LM; Chu PG
    Mod Pathol; 2007 Mar; 20(3):320-5. PubMed ID: 17277761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
    Ulbright TM
    Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas.
    Gopalan A; Dhall D; Olgac S; Fine SW; Korkola JE; Houldsworth J; Chaganti RS; Bosl GJ; Reuter VE; Tickoo SK
    Mod Pathol; 2009 Aug; 22(8):1066-74. PubMed ID: 19396148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deregulation of EZH2 expression in human spermatogenic disorders and testicular germ cell tumors.
    Hinz S; Magheli A; Weikert S; Schulze W; Krause H; Schrader M; Miller K; Kempkensteffen C
    World J Urol; 2010 Oct; 28(5):631-5. PubMed ID: 20043168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G9a/EHMT2 is a Potential Prognostic Biomarker and Molecular Target in SHH Medulloblastoma.
    Souza BK; Freire NH; Jaeger M; de Farias CB; Brunetto AL; Brunetto AT; Roesler R
    Neuromolecular Med; 2022 Dec; 24(4):392-398. PubMed ID: 35113321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone Methyltransferases G9a/
    Souza BK; Freire NH; Monteiro TS; Herlinger AL; Jaeger M; Dalmolin MGS; de Farias CB; Gregianin L; Brunetto AT; Brunetto AL; Thiele CJ; Roesler R
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Burned-out testicular germ cell tumors: a clinicopathological analysis of three cases].
    Ni YP; Zhang ZH; Chen XY; Liu JS; Yang XQ
    Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):347-352. PubMed ID: 36973194
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of intratubular seminoma and intratubular embryonal carcinoma with invasive testicular germ cell tumors.
    Lau SK; Weiss LM; Chu PG
    Am J Surg Pathol; 2007 Jul; 31(7):1045-9. PubMed ID: 17592271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wnt suppressor and stem cell regulator TCF7L1 is a sensitive immunohistochemical marker to differentiate testicular seminoma from non-seminomatous germ cell tumor.
    Bu L; Yang Q; McMahon L; Xiao GQ; Li F
    Exp Mol Pathol; 2019 Oct; 110():104293. PubMed ID: 31381875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G9a in Cancer: Mechanisms, Therapeutic Advancements, and Clinical Implications.
    Ni Y; Shi M; Liu L; Lin D; Zeng H; Ong C; Wang Y
    Cancers (Basel); 2024 Jun; 16(12):. PubMed ID: 38927881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors.
    Bode PK; Barghorn A; Fritzsche FR; Riener MO; Kristiansen G; Knuth A; Moch H
    Mod Pathol; 2011 Jun; 24(6):829-35. PubMed ID: 21780320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recently discovered EZH2 and EHMT2 (G9a) inhibitors.
    Soumyanarayanan U; Dymock BW
    Future Med Chem; 2016 Sep; 8(13):1635-54. PubMed ID: 27548656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: investigation of biomarkers.
    Lobo J; Gillis AJM; van den Berg A; Looijenga LHJ
    BMC Cancer; 2020 Aug; 20(1):728. PubMed ID: 32758242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lysine methyltransferase Ehmt2/G9a is dispensable for skeletal muscle development and regeneration.
    Zhang RH; Judson RN; Liu DY; Kast J; Rossi FM
    Skelet Muscle; 2016; 6():22. PubMed ID: 27239264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Inhibition of G9a and EZH2 Suppresses Tumor Growth via Synergistic Induction of IL24-Mediated Apoptosis.
    Casciello F; Kelly GM; Ramarao-Milne P; Kamal N; Stewart TA; Mukhopadhyay P; Kazakoff SH; Miranda M; Kim D; Davis FM; Hayward NK; Vertino PM; Waddell N; Gannon F; Lee JS
    Cancer Res; 2022 Apr; 82(7):1208-1221. PubMed ID: 35149587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.